Dry powder PA-824 aerosols for treatment of tuberculosis in guinea pigs

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 4, 2010, Pages 1436-1442

  Garcia Contreras, Lucila ^a   Sung, Jean C ^b   Muttil, Pavan ^a   Padilla, Danielle ^a   Telko, Martin ^a   Verberkmoes, Jarod L ^b   Elbert, Katharina J ^b   Hickey, Anthony J ^a   Edwards, David A ^b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b HARVARD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6,7 DIHYDRO 2 NITRO 6 (4 TRIFLUOROMETHOXYBENZYLOXY) 5H IMIDAZO[2,1 B][1,3]OXAZINE; CYCLODEXTRIN; PHOSPHATIDYLCHOLINE; PLACEBO;

AEROSOL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL COUNT; CONTROLLED STUDY; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG MEGADOSE; DRY POWDER; GUINEA PIG; HISTOPATHOLOGY; INFLAMMATION; LOW DRUG DOSE; LUNG; MALE; NONHUMAN; PRIORITY JOURNAL; SPLEEN; TUBERCULOSIS;

ADMINISTRATION, INHALATION; ADMINISTRATION, ORAL; AEROSOLS; ANIMALS; ANTITUBERCULAR AGENTS; CHEMISTRY, PHARMACEUTICAL; COLONY COUNT, MICROBIAL; DISEASE MODELS, ANIMAL; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; GUINEA PIGS; HUMANS; LATENT TUBERCULOSIS; LUNG; MALE; NITROIMIDAZOLES; PARTICLE SIZE; POWDERS; SPLEEN; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY;

EID: 77950101234     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01471-09     Document Type: Article

References (28)

1. Bates, D. V., B. R. Fish, T. F. Hatch, T. T. Mercer, and P. E. Morrow. 1966. Deposition and retention models for internal dosimetry of the human respiratory. Task Group on Lung Dynamics. Health Physics 12: 173-207.
2. Demidov, S. V., V. G. Myasnikov, E. F. Chernushenko, and L. S. Osipova. 1991. Effects of thymus preparations and antituberculous drugs on immunological reactivity and the course of tuberculous process in experimental animals. Problemy Tuberkuleza 12:52-54.
3. Devi, T. I., R. P. Gupta, R. K. Dhawan, V. V. S. Murti, B. Ramamurthy, T. Ramakrishnan, and T. A. Venkitasubramanian. 1988. Chemotherapy of experimental tuberculosis with N-(2-naphthyl)glycine hydrazide dihydrochloride. Part I. Acute toxity and effect on wet weight, dry weight, glycogen and total lipids of organs. Indian J. Clin. Biochem. 3:37-44.
4. Drandarska, I., V. Kussovski, S. Nikolaeva, and N. Markova. 2005. Combined immunomodulating effects of BCG and Lentinan after intranasal application in guinea pigs. Int. Immunopharmacol. 5:795-803.
5. Edwards, D. A., J. Hanes, G. Caponetti, J. Hrkach, A. Ben-Jebria, M. L. Eskew, J. Mintzes, D. Deaver, N. Lotan, and R. Langer. 1997. Large porous particles for pulmonary drug delivery. Science 276:1868-1872.
6. Fiegel, J., L. Garcia-Contreras, M. Thomas, J. VerBerkmoes, K. Elbert, A. Hickey, and D. Edwards. 2008. Preparation and in vivo evaluation of a dry powder for inhalation of capreomycin. Pharm. Res. 25:805-811.
7. Garcia-Contreras, L., J. Fiegel, M. J. Telko, K. Elbert, A. Hawi, M. Thomas, J. VerBerkmoes, W. A. Germishuizen, P. B. Fourie, A. J. Hickey, and D. Edwards. 2007. Inhaled large porous particles of capreomycin for treatment of tuberculosis in a guinea pig model. Antimicrob. Agents Chemother. 51: 2830-2836.
8. Ginsberg, A. M., M. W. Laurenzi, D. J. Rouse, K. D. Whitney, and M. K. Spigelman. 2009. Assessment of the effects of the nitroimidazo-oxazine, PA-824, on renal function in healthy subjects. Antimicrob. Agents Chemother. 53:3726-3733.
9. Ginsberg, A. M., M. W. Laurenzi, D. J. Rouse, K. D. Whitney, and M. K. Spigelman. 2009. Safety, tolerability, and pharmacokinetics of PA-824 in healthy subjects. Antimicrob. Agents Chemother. 53:3720-3725.
10. Jiang, S., D. Zhu, Y. Jiang, X. Luo, and Q. Chen. 2005. Therapeutic effect of eukaryotic expression plasmid psIL-12 on murine infection with Mycobacterium tuberculosis. Zhonghua Yi Xue Za Zhi 24:373-376. (In Chinese.)
11. Lenaerts, A. J., V. Gruppo, K. S. Marietta, C. M. Johnson, D. K. Driscoll, N. M. Tompkins, J. D. Rose, R. C. Reynolds, and I. M. Orme. 2005. Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models. Antimicrob. Agents Chemother. 49:2294-2301.
12. Mainali, E. S., and D. N. McMurray. 1998. Protein deficiency induces alterations in the distribution of T-cell subsets in experimental pulmonary tuberculosis. Infect. Immun. 66:927-931.
13. Manjunatha, U. H., H. Boshoff, C. S. Dowd, L. Zhang, T. J. Albert, J. E. Norton, L. Daniels, T. Dick, S. S. Pang, and C. E. Barry. 2006. Identification of a nitroimidazo-oxazine-specific protein involved in PA-824 resistance in Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. U. S. A. 103:431-436.
14. McMurray, D. N. 1994. Guinea pig model of tuberculosis, p. 135-148. In B. R. Bloom (ed.), Tuberculosis: pathogenesis, protection, and control. ASM Press, Washington, DC.
15. Niu, X., C. Liu, Y. Li, M. Li, and H. Wang. 1998. Therapeutic action of Luolining capsules on tuberculotic guinea pigs. Zhongguo Yaoke Daxue Xuebao 29:142-144.
16. Nuermberger, E., I. Rosenthal, S. Tyagi, K. N. Williams, D. Almeida, C. A. Peloquin, W. R. Bishai, and J. H. Grosset. 2006. Combination chemotherapy with the nitroimidazopyran PA-824 and first-line drugs in a murine model of tuberculosis. Antimicrob. Agents Chemother. 50: 2621-2625.
17. Nuermberger, E., S. Tyagi, R. Tasneen, K. N. Williams, D. Almeida, I. Rosenthal, and J. H. Grosset. 2008. Powerful bactericidal and sterilizing activity of a regimen containing PA-824, moxifloxacin, and pyrazinamide in a murine model of tuberculosis. Antimicrob. Agents Chemother. 52:1522-1524.
18. Nuermberger, E., S. Tyagi, K. N. Williams, I. Rosenthal, W. R. Bishai, and J. H. Grosset. 2005. Rifapentine, moxifloxacin, or DNA vaccine improves treatment of latent tuberculosis in a mouse model. Am. J. Respir. Crit. Care Med. 172:1452-1456.
19. O'Brien, R. J., and M. K. Spigelman. 2005. New drugs for tuberculosis: current status and future prospects. Clin. Chest Med. 26:327-340.
20. Sacchettini, J. C., E. J. Rubin, and J. S. Freundlich. 2008. Drugs versus bugs: in pursuit of the persistent predator Mycobacterium tuberculosis. Nat. Rev. Microbiol. 6:41-52.
21. Sacks, L. V., S. Pendle, D. Orlovic, M. Andre, M. Popara, G. Moore, L. Thonell, and S. Hurwitz. 2001. Adjunctive salvage therapy with inhaled aminoglycosides for patients with persistent smear-positive pulmonary tuberculosis. Clin. Infect. Dis. 32:44-49.
22. Snipes, M. B. 1989. Long-term retention and clearance of particles inhaled by mammalian species. Crit. Rev. Toxicol. 20:175-211.
23. Spigelman, M. K. 2007. New tuberculosis therapeutics: a growing pipeline. J. Infect. Dis. 196:S28-S34.
24. Stover, C. K., P. Warrener, D. R. VanDevanter, D. R. Sherman, T. M. Arain, M. H. Langhorne, S. W. Anderson, J. A. Towell, Y. Yuan, D. N. McMurray, B. N. Kreiswirth, C. E. Barry, and W. R. Baker. 2000. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature 405:962.
25. Sung, J. C., L. Garcia-Contreras, J. L. Verberkmoes, C. A. Peloquin, K. J. Elbert, A. J. Hickey, and D. A. Edwards. 2009. Dry powder nitroimidazopyran antibiotic PA-824 aerosol for inhalation. Antimicrob. Agents Chemother. 53:1338-1343.
26. Tyagi, S., E. Nuermberger, T. Yoshimatsu, K. Williams, I. Rosenthal, N. Lounis, W. Bishai, and J. Grosset. 2005. Bactericidal activity of the nitroimidazopyran PA-824 in a murine model of tuberculosis. Antimicrob. Agents Chemother. 49:2289-2293.
27. Wiegeshaus, E. H., D. N. McMurray, A. A. Grover, G. E. Harding, and D. W. Smith. 1970. Host-parasite relationships in experimental airborne tuberculosis. 3. Relevance of microbial enumeration to acquired resistance in guinea pigs. Am. Rev. Respir. Dis. 102:422-428.
28. Williams, K. J., and K. Duncan. 2007. Current strategies for identifying and validating targets for new treatment-shortening drugs for TB. Curr. Mol. Med. 7:297-307.